[go: up one dir, main page]

SG11201504865YA - Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors - Google Patents

Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors

Info

Publication number
SG11201504865YA
SG11201504865YA SG11201504865YA SG11201504865YA SG11201504865YA SG 11201504865Y A SG11201504865Y A SG 11201504865YA SG 11201504865Y A SG11201504865Y A SG 11201504865YA SG 11201504865Y A SG11201504865Y A SG 11201504865YA SG 11201504865Y A SG11201504865Y A SG 11201504865YA
Authority
SG
Singapore
Prior art keywords
kinase inhibitors
substituted pyridine
carboxamide compounds
apoptosis signal
regulating kinase
Prior art date
Application number
SG11201504865YA
Inventor
Gregory Notte
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201504865YA publication Critical patent/SG11201504865YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201504865YA 2012-12-21 2013-12-20 Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors SG11201504865YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740777P 2012-12-21 2012-12-21
PCT/US2013/076811 WO2014100541A1 (en) 2012-12-21 2013-12-20 Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201504865YA true SG11201504865YA (en) 2015-07-30

Family

ID=49943575

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504865YA SG11201504865YA (en) 2012-12-21 2013-12-20 Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors

Country Status (29)

Country Link
US (4) US9051313B2 (en)
EP (2) EP3150597A1 (en)
JP (2) JP6086633B2 (en)
KR (1) KR101712758B1 (en)
CN (1) CN104918936B (en)
AR (1) AR094214A1 (en)
AU (2) AU2013361140B2 (en)
BR (1) BR112015014567A2 (en)
CA (1) CA2896060C (en)
CY (1) CY1118574T1 (en)
DK (1) DK2935258T3 (en)
EA (1) EA027645B1 (en)
ES (1) ES2612979T3 (en)
HK (1) HK1214247A1 (en)
HR (1) HRP20170112T8 (en)
HU (1) HUE032988T2 (en)
IL (2) IL239322A (en)
LT (1) LT2935258T (en)
MX (1) MX2015008090A (en)
NZ (1) NZ709248A (en)
PL (1) PL2935258T3 (en)
PT (1) PT2935258T (en)
RS (1) RS55676B1 (en)
SG (1) SG11201504865YA (en)
SI (1) SI2935258T1 (en)
SM (2) SMT201700051T1 (en)
TW (1) TWI622589B (en)
UY (1) UY35212A (en)
WO (1) WO2014100541A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI625121B (en) 2009-07-13 2018-06-01 基利科學股份有限公司 Inhibitor of kinases that regulate apoptosis signaling
AU2011272782B2 (en) * 2010-07-02 2014-11-27 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
UY35212A (en) * 2012-12-21 2014-06-30 Gilead Sciences Inc INHIBITORS OF THE KINASE THAT REGULATES THE SIGNAL OF APOPTOSIS
JP2016540029A (en) 2013-12-20 2016-12-22 ギリアード サイエンシーズ, インコーポレイテッド Apoptosis signal-regulating kinase inhibitor
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
TW201618781A (en) * 2014-08-13 2016-06-01 吉李德科學股份有限公司 Methods of treating pulmonary hypertension
SG11201701723XA (en) 2014-09-24 2017-04-27 Gilead Sciences Inc Methods of treating liver disease
CN112225699B (en) 2014-12-23 2023-11-14 吉利德科学公司 Process for preparing ASK1 inhibitors
MA41252A (en) 2014-12-23 2017-10-31 Gilead Sciences Inc SOLID FORMS OF AN ASK 1 INHIBITOR
WO2018090869A1 (en) * 2016-11-16 2018-05-24 广东东阳光药业有限公司 Amide derivative and use thereof in medicine
WO2018094964A1 (en) * 2016-11-25 2018-05-31 武汉大学 Method with apoptotic signal-regulated kinase 1n-dimerization serving as target for screening medicament use for treating steatohepatitis
CN109963570A (en) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 Application of paeoniflorin-6'-O-benzenesulfonate in the treatment of Sjögren's syndrome
CN109071448B (en) * 2017-01-22 2020-03-17 福建广生堂药业股份有限公司 ASK1 inhibitor and preparation method and application thereof
WO2018157856A1 (en) * 2017-03-03 2018-09-07 江苏豪森药业集团有限公司 Amide derivative inhibitor and preparation method and application thereof
JP7377718B2 (en) 2017-05-12 2023-11-10 エナンタ ファーマシューティカルズ インコーポレイテッド Apoptosis signal-regulated kinase 1 inhibitor and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10450301B2 (en) 2017-05-25 2019-10-22 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019047094A1 (en) * 2017-09-07 2019-03-14 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
US10370352B2 (en) 2017-09-07 2019-08-06 Eli Lilly And Company Cyclobutyl-imidazolidinone compounds
WO2019099703A1 (en) * 2017-11-16 2019-05-23 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
WO2019099203A1 (en) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Oxazole and thiazole derivatives as inhibitors of ask1
CN110407806B (en) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 Carboxamide compounds, preparation method and application thereof
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
IL278368B2 (en) * 2018-05-02 2024-06-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
BR112020026423A2 (en) * 2018-06-27 2021-03-23 Biogen Ma Inc. ask1 inhibitory agents
WO2020030107A1 (en) * 2018-08-10 2020-02-13 江苏豪森药业集团有限公司 Pharmaceutical composition containing amide derivatives, preparation method therefor, and application thereof
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
UY28323A1 (en) * 2003-05-21 2004-12-31 Boehringer Ingelheim Int INHIBITING COMPOUNDS OF HEPATITIS C
JPWO2005009470A1 (en) 2003-07-28 2006-09-28 財団法人大阪産業振興機構 Heart failure therapeutic agent containing an ASK1 inhibitor as an active ingredient and screening method thereof
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
US20100144793A1 (en) 2006-11-24 2010-06-10 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
TWI625121B (en) * 2009-07-13 2018-06-01 基利科學股份有限公司 Inhibitor of kinases that regulate apoptosis signaling
AU2011272782B2 (en) * 2010-07-02 2014-11-27 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
UY35212A (en) * 2012-12-21 2014-06-30 Gilead Sciences Inc INHIBITORS OF THE KINASE THAT REGULATES THE SIGNAL OF APOPTOSIS
JP2016540029A (en) * 2013-12-20 2016-12-22 ギリアード サイエンシーズ, インコーポレイテッド Apoptosis signal-regulating kinase inhibitor

Also Published As

Publication number Publication date
CN104918936A (en) 2015-09-16
JP6086633B2 (en) 2017-03-01
KR20150095903A (en) 2015-08-21
US20170173031A1 (en) 2017-06-22
DK2935258T3 (en) 2017-02-13
IL255799B (en) 2018-11-29
US9943521B2 (en) 2018-04-17
JP2016222721A (en) 2016-12-28
HUE032988T2 (en) 2017-11-28
CA2896060A1 (en) 2014-06-26
UY35212A (en) 2014-06-30
EA027645B1 (en) 2017-08-31
BR112015014567A2 (en) 2017-07-11
TWI622589B (en) 2018-05-01
PL2935258T3 (en) 2017-06-30
IL255799A (en) 2018-01-31
US10307427B2 (en) 2019-06-04
AU2016247182A1 (en) 2016-11-10
IL239322A (en) 2017-12-31
US20150246910A1 (en) 2015-09-03
AR094214A1 (en) 2015-07-15
AU2013361140A1 (en) 2015-07-09
SMT201700051T1 (en) 2017-03-08
CA2896060C (en) 2017-03-21
SMT201700051B (en) 2017-03-08
EP2935258B1 (en) 2016-11-02
JP2016503801A (en) 2016-02-08
LT2935258T (en) 2017-02-10
PT2935258T (en) 2017-02-09
RS55676B1 (en) 2017-06-30
NZ709248A (en) 2016-04-29
MX2015008090A (en) 2016-04-11
KR101712758B1 (en) 2017-03-06
HK1214247A1 (en) 2016-07-22
HRP20170112T1 (en) 2017-03-24
WO2014100541A1 (en) 2014-06-26
AU2016247182B2 (en) 2017-12-21
EA201591018A1 (en) 2016-01-29
IL239322A0 (en) 2015-07-30
US20140179663A1 (en) 2014-06-26
CN104918936B (en) 2018-04-27
SI2935258T1 (en) 2017-02-28
US9051313B2 (en) 2015-06-09
US20180303844A1 (en) 2018-10-25
EP3150597A1 (en) 2017-04-05
HRP20170112T8 (en) 2017-06-16
TW201441221A (en) 2014-11-01
EP2935258A1 (en) 2015-10-28
AU2013361140B2 (en) 2016-11-03
CY1118574T1 (en) 2017-07-12
ES2612979T3 (en) 2017-05-19

Similar Documents

Publication Publication Date Title
IL255799A (en) Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors
IL257965A (en) Apoptosis signal-regulating kinase inhibitor
IL261282A (en) Purinone compounds as kinase inhibitors
IL247405A0 (en) Apoptosis signal-regulating kinase inhibitors
IL245807A0 (en) Apoptosis signal-regulating kinase inhibitors
IL238728A0 (en) Pyrrolopyrimidine compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
IL234183A (en) Pyrazolotriazine derivatives as selective cyclin-dependent kinase inhibitors
HUE044146T2 (en) Pyrazolopyrimidine compounds as kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
EP2900639A4 (en) Bicyclic dihydropyridone kinase inhibitors
EP2903970A4 (en) Substituted pyrimidinyl kinase inhibitors
EP2847186A4 (en) Substituted aminoquinazolines useful as kinases inhibitors
EP2758387A4 (en) Pyridine compounds as inhibitors of kinase
EP2900243A4 (en) Bicyclic oxa-lactam kinase inhibitors
IL235935A0 (en) Substituted picolinamide kinase inhibitors